National Cancer Institute Thesaurus

Last uploaded: March 26, 2019
Preferred Name

Nintedanib

Synonyms

BIBF 1120

Multitargeted Tyrosine Kinase Inhibitor BIBF 1120

tyrosine kinase inhibitor BIBF 1120

Vargatef

Intedanib

Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate

NINTEDANIB

Nintedanib

BIBF-1120

Definitions

An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3). VEGFR, FGFR and PDGFR RTKs play key roles in tumor angiogenesis.

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C62765

ALT_DEFINITION

A substance being studied in the treatment of some types of cancer. BIBF 1120 blocks enzymes needed for cells to grow, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.

CAS_Registry

656247-17-5

Chemical_Formula

C31H33N5O4

code

C62765

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

Contributing_Source

CTRP

FDA

DEFINITION

An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3). VEGFR, FGFR and PDGFR RTKs play key roles in tumor angiogenesis.

Display_Name

Nintedanib

FDA_UNII_Code

G6HRD2P839

FULL_SYN

BIBF 1120

Multitargeted Tyrosine Kinase Inhibitor BIBF 1120

tyrosine kinase inhibitor BIBF 1120

Vargatef

Intedanib

Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate

NINTEDANIB

Nintedanib

BIBF-1120

Has_Salt_Form

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154570

label

Nintedanib

Legacy_Concept_Name

BIBF_1120

PDQ_Closed_Trial_Search_ID

504524

PDQ_Open_Trial_Search_ID

504524

Preferred_Name

Nintedanib

prefixIRI

ncit:C62765

Semantic_Type

Pharmacologic Substance

UMLS_CUI

C2930789

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1742

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155727

Delete Subject Author Type Created
No notes to display